Typhoid fever vaccines market

Typhoid fever, also simply called as typhoid is a bacterial infection caused by Salmonella typhi, also known as Salmonella enterica serotype Typhi. The typhoid fever is usually caused due to ingestion of contaminated food or water. Typhoid vaccine prevents typhoid fever and provides protection against it. The World Health Organization (WHO) has recommended three typhoid vaccines for use, which include live attenuated vaccine, capsular polysaccharide vaccine, and conjugate vaccine.  

Global typhoid fever vaccines market is estimated to be valued at US$ 351.4 million in 2022 and is expected to exhibit a CAGR of 12.2% during the forecast period (2022-2030).

Figure 1. Global Typhoid Fever Vaccines Market Share (%), by Vaccine Type, 2022

Increasing government initiatives for rising awareness regarding typhoid vaccines is expected to drive the global typhoid fever vaccines market growth.

Increasing government initiatives for rising awareness regarding typhoid vaccines is expected to drive the global typhoid fever vaccines market growth over the forecast period. Organizations such as World Health Organization (WHO), Gavi, Bill & Melinda Gates Foundation, and others are highly active in creating awareness regarding typhoid and driving immunization efforts against such diseases. For instance, in October 2017, WHO recommended introduction of typhoid vaccine for children over six months in endemic countries. It also recommended catch-up vaccination whenever possible, prioritizing children and adolescents up to 15 years of age. Moreover, World Health Organization (WHO), pre-qualified a typhoid conjugate vaccine (TCV) Typbar TCV, manufactured by Bharat Biotech, Biotechnology company in December 2017. WHO pre-qualification enables the procurement and supply of this vaccine to United Nations International Children's Emergency Fund, the Pan-American Health Organization (PAHO), and GAVI (a vaccine alliance) supported countries. Such frequent initiatives taken by various organizations is expected to drive the market growth over the forecast period.

Figure 2. Global Typhoid Fever Vaccines Market Share (%), by Region, 2022

High prevalence of typhoid in various emerging economies is expected to drive the global typhoid fever vaccines market growth during the forecast period.

High prevalence of typhoid in various emerging economies is expected to drive the global typhoid fever vaccines market growth during the forecast period. For instance, in November 2021, according to the data published by the World Health Organization, Typhoid fever has an estimated global incidence of 11–21 million cases annually, resulting in 12,0 000–16,0 000 deaths. Every year, an estimated 11–20 million people get sick from typhoid and between 128 000 and 161 000 people die from it worldwide. In 2017, over 10 million typhoid fever cases occurred globally, causing over 116,000 deaths.

Global Typhoid Fever Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global typhoid fever vaccines market, owing to the disruption in delivery and healthcare services during COVID 19 pandemic. For instance, in July 2020, according to the data published by the National Center for Biotechnology Information, due to disruptions in the delivery and uptake of immunization services caused by the COVID-19 pandemic. In 2019, UNICEF procured an estimated 2.43 billion doses of vaccines to around 100 countries to reach around 45% of the world’s children below the 5-year-old age group. COVID-19-induced disruption of routine vaccination affected lives of infants.

Global Typhoid Fever Vaccines Market: Key Developments                                

In April 2022, the Ministry of Health and Population, Gavi, the Vaccine Alliance, UNICEF, WHO and other partners were collaborating on the worldwide typhoid vaccine introduction including a catch-up campaign, which seeks to vaccinate all children from the age of 15 months to 15 years to protect them from typhoid fever. With support from Gavi, the Vaccine Alliance, WHO, UNICEF and other partners, the Government of Nepal launched a new vaccine campaign in April 2022 introducing Typhoid Conjugate Vaccine (TCV) into the routine immunization programme across the country. The three-week campaign, which ran from April 7 2022 to May 1 2022, aimed to reach all children between 15 months and 15 years to quickly achieve wider protection from typhoid, increase the impact of the vaccine introduction and combat the rise of antimicrobial resistance.

Global Typhoid Fever Vaccines Market: Restraint

The major factors that hinder growth of the global typhoid fever vaccines market include lack of healthcare infrastructure and the skilled professionals. Additionally, side effects of typhoid fever vaccine such as pain and mild fever will act as a restrain for the global typhoid fever vaccines market.

Key Players

Major players operating in the global typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.

Detailed Segmentation:

• Global Typhoid Fever Vaccines Market, By Vaccine Type:
  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
  • Others
• Global Typhoid Fever Vaccines Market, By Route of Administration:
  • Oral
  • Parenteral
• Global Typhoid Fever Vaccines Market, By Region:
  • North America
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
    • By Route of Administration:
      • Oral
      • Parenteral
    • By Region
      • South Africa
      • Central Africa
      • North Africa